Chang Kochi 4

What Happened
Chang Kochi, a director of YD Bio Ltd (YDES), was granted 2,081 restricted share units (RSUs) on March 31, 2026 and the filing also reports conversion/exercise of derivative rights for 2,081 ordinary shares. The grant has an aggregate target grant-date fair value of $60,000. The reported acquisitions show a $0 per-share purchase price — i.e., no cash was paid by the insider to receive the shares (award/derivative conversion).

Key Details

• Transaction date: March 31, 2026; Form 4 filed April 2, 2026 (appears timely).
• Reported transactions: Grant/Award (code A) of 2,081 RSUs; Exercise/Conversion of derivative (code M) reporting acquisition of 2,081 shares (the filing records both the grant and the conversion).
• Price paid: $0.00 per share (non-cash award/conversion).
• Grant value: Aggregate target grant-date fair value $60,000 for the RSUs.
• Vesting/settlement terms (footnotes): Each RSU represents a contingent right to one ordinary share. The Granted RSUs vest in four equal quarterly installments beginning March 31, 2026, with the number of RSUs subject to each vesting determined by dividing $15,000 by the 7-trading-day VWAP ending on the trading day prior to each vesting date. The reporting person became entitled to a fixed number of RSUs on March 31, 2026.
• Shares owned after transaction: Not disclosed in the filing.

Context
This reporting reflects an equity award (RSUs) and their conversion into ordinary shares rather than an open-market purchase or sale. No sale was reported here. For retail investors, awards and conversions at $0 typically reflect compensation or incentive plan activity rather than an insider's cash investment; they do not necessarily indicate buy/sell sentiment.